epithalon peptide what is (Epitalon) - 10mg Epithalon 10mg | Research Peptide

2010 Dec 9;363(24):2320-31

Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Our entire body naturally produces peptides, but as we age, these numbers steadily decrease

Mulla, M.H

Schedule an appointment with a McAllen med spa clinician today and take the next step toward a healthier you.